Roche Maps Out Its ‘Top Three In Obesity’ Ambition

 
• By Andrew McConaghie
  
The average GLP-1 agonist patient today has a high BMI of 39 - Roche believes the market can be expanded to those with much lower scores.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Therapy Areas